Products

Mitant 12.5mg Capsule (Sunitinib) Detailed Product Information: What is Mitant 12.5 mg? Mitant 12.5 mg is an advanced oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Mitant is a “multi-targeted“ therapy, meaning it interferes with specific pathways that cancer cells use to grow, divide, and spread throughout the body. The 12.5mg dosage is often used for precise dose titration, allowing oncologists to adjust treatment based on patient tolerance and therapeutic response. Primary Therapeutic Indications Gastrointestinal Stromal Tumor (GIST): Used for patients with stomach or bowel tumors that have progressed or for those who cannot tolerate other treatments. Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Helps prevent the recurrence of kidney cancer in high-risk patients following surgery. Mechanism of Action: How Mitant Works Mitant 12.5 mg employs a multi-pronged approach to stop cancer progression: Signal Inhibition: It blocks the Tyrosine Kinase enzymes found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Mitant prevents the “growth“ command from reaching the cell nucleus. Anti-Angiogenesis: It targets VEGF (Vascular Endothelial Growth Factor) receptors. This prevents the tumor from growing new blood vessels. By cutting off the blood supply, the tumor is starved of oxygen and nutrients. Metastasis Suppression: By disrupting cellular signaling, it inhibits the ability of malignant cells to migrate to other organs. Detailed Clinical Instructions To ensure the safety and efficacy of Sunitinib therapy, strictly follow these guidelines: Dosage: The 12.5 mg dose is often used for precise titration or as part of a specific combination regimen. Always follow the exact dosage prescribed by your oncologist. Administration: Swallow the capsule whole with water. You may take it with or without food. Integrity: Do not crush, chew, or open the capsule. Consistency: Take your dose at the same time every day to maintain steady blood levels. Cycle Management: Mitant is frequently taken in cycles (e.g., 4 weeks on, 2 weeks off). Do not skip days unless instructed by a physician. Potential Side Effects As a potent anti-cancer agent, Mitant 12.5mg can cause adverse reactions. Common side effects include: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Skin discoloration (yellowing of the skin), dryness, or hand-foot syndrome (painful redness and swelling on the palms and soles). Cardiovascular: High blood pressure (hypertension). Regular monitoring is required. Systemic: Fatigue, weakness, and decreased appetite. Hematological: Potential for decreased blood cell counts (Anemia or Neutropenia). Storage and Handling Requirements Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep out of reach of children and pets. Handle with care; do not touch the powder if a capsule is accidentally broken. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products meet the highest international manufacturing standards. ✔ Worldwide Strategic Logistics: Expertise in shipping to USA, UK, UAE, Australia, and Singapore. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA, invoices, and customs documentation for seamless delivery. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutekast 50mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sutekast 50mg? Sutekast 50mg is a high-potency oral oncology medication containing the active pharmaceutical ingredient Sunitinib. Classified as a multikinase inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that attacks all rapidly dividing cells, Sutekast is designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sutekast Disrupts Cancer Sutekast 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sutekast stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sutekast targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sutekast is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects Sutekast 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sunitinib 50mg Capsule Comprehensive Product Profile: What is Sunitinib 50mg? Sunitinib 50 mg is a potent, multi-targeted oral oncology medication. Classified as a Tyrosine Kinase Inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that attacks all rapidly dividing cells, Sunitinib is designed to target specific molecular pathways that allow tumors to survive and thrive. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite other therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sunitinib Works Sunitinib 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sunitinib stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sunitinib targets vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sunitinib is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects Sunitinib 50 mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or hand-foot syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutinat 12.5mg Capsule (Sunitinib) Detailed Product Information: What is Sutinat 12.5mg? Sutinat 12.5mg is an advanced oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Sutinat is a “multi-targeted“ therapy, meaning it interferes with specific pathways that cancer cells use to grow, divide, and spread throughout the body. Primary Therapeutic Indications Gastrointestinal Stromal Tumor (GIST): Used for patients with stomach or bowel tumors that have progressed or for those who cannot tolerate other treatments. Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Helps prevent the recurrence of kidney cancer in high-risk patients following surgery. Mechanism of Action: How Sutinat Works Sutinat 12.5mg employs a multi-pronged approach to stop cancer progression: Signal Inhibition: It blocks the Tyrosine Kinase enzymes found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Sutinat prevents the “growth“ command from reaching the cell nucleus. Anti-Angiogenesis: It targets VEGF (Vascular Endothelial Growth Factor) receptors. This prevents the tumor from growing new blood vessels. By cutting off the blood supply, the tumor is deprived of oxygen and nutrients. Metastasis Suppression: By disrupting cellular signaling, it inhibits the ability of malignant cells to migrate to other organs. Detailed Clinical Instructions To ensure the safety and efficacy of sunitinib therapy, strictly follow these guidelines: Dosage: The 12.5 mg dose is often used for precise titration or as part of a specific combination regimen. Always follow the exact dosage prescribed by your oncologist. Administration: Swallow the capsule whole with water. You may take it with or without food. Integrity: Do not crush, chew, or open the capsule. Consistency: Take your dose at the same time every day to maintain steady blood levels. Cycle Management: Sutinat is frequently taken in cycles (e.g., 4 weeks on, 2 weeks off). Do not skip days unless instructed by a physician. Potential Side Effects As a potent anti-cancer agent, Sutinat 12.5 mg can cause adverse reactions. Common side effects include: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Skin discoloration (yellowing of the skin), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: High blood pressure (hypertension). Regular monitoring is required. Systemic: Fatigue, weakness, and decreased appetite. Hematological: Potential for decreased blood cell counts (Anemia or Neutropenia). Storage and Handling Requirements Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep out of reach of children and pets. Handle with care; do not touch the powder if a capsule is accidentally broken. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products meet the highest international manufacturing standards. ✔ Worldwide Strategic Logistics: Expertise in shipping to USA, UK, UAE, Australia, and Singapore. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA, invoices, and customs documentation for seamless delivery. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sugistran 50mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sugistran 50mg? Sugistran 50mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. Classified as a multikinase inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that non-selectively attacks all rapidly dividing cells, Sugistran is designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sugistran Disrupts Cancer Sugistran 50 mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases located on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sugistran stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sugistran targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Metastasis Suppression: By disrupting vital survival pathways, the medication helps slow the spread of malignant cells to other parts of the body. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sugistran is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects Sugistran 50 mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Partner with Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Nitnib 50mg Capsule (Sunitinib) Detailed Product Overview: What is Nitnib 50mg? Nitnib 50mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. It is classified as a multikinase inhibitor (TKI) and is a cornerstone in the field of targeted cancer therapy. Unlike traditional chemotherapy, which non-selectively attacks all rapidly dividing cells, Nitnib is designed to identify and interfere with specific molecular pathways involved in the growth, progression, and spread of cancer cells. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to imatinib therapy. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer returning in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Nitnib Works Nitnib 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the biological infrastructure of a tumor. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals that tell the cancer cells to multiply. By blocking these signals, Nitnib halts uncontrolled cell division. Anti-Angiogenesis Strategy: Nitnib inhibits the Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This prevents the tumor from developing its own blood vessels. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Clinical Instructions & Administration To ensure maximum therapeutic efficacy and safety, follow these administration guidelines: Dosing Schedule: Nitnib is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Side Effects & Management Nitnib 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Disposal: Do not dispose of oncology medications in household wastewater. Consult your local pharmacist for proper hazardous waste disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Rcnet 50mg Capsule (Sunitinib) Detailed Product Overview: What is Rcnet 50mg? Rcnet 50mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. It is classified as a multikinase inhibitor (TKI) and is a cornerstone in the field of targeted cancer therapy. Unlike traditional chemotherapy, which non-selectively attacks all rapidly dividing cells, Rcnet is designed to identify and interfere with specific molecular pathways involved in the growth, progression, and spread of cancer cells. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to imatinib. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer returning in high-risk patients following a nephrectomy. Mechanism of Action: How Rcnet Works Rcnet 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the biological infrastructure of a tumor. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals that tell the cancer cells to multiply. By blocking these signals, Rcnet halts uncontrolled cell division. Anti-Angiogenesis Strategy: Rcnet inhibits the Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This prevents the tumor from developing its own blood supply. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Clinical Instructions & Administration To ensure maximum therapeutic efficacy and safety, follow these administration guidelines: Dosing Schedule: Rcnet is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Side Effects & Management Rcnet 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Disposal: Do not dispose of oncology medications in household wastewater. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Detailed Product Overview: What is Sutinat 50mg? Sutinat 50 mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. It is classified as a multikinase inhibitor (TKI) and is a cornerstone in the field of targeted cancer therapy. Unlike traditional chemotherapy, which non-selectively attacks all rapidly dividing cells, Sutinat is designed to identify and interfere with specific molecular pathways involved in the growth, progression, and spread of cancer cells. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to imatinib. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer returning in high-risk patients following a nephrectomy. Mechanism of Action: How Sutinat Works Sutinat 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the biological infrastructure of a tumor. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals that tell the cancer cells to multiply. By blocking these signals, Sutinat halts uncontrolled cell division. Anti-Angiogenesis Strategy: Sutinat inhibits the Vascular Endothelial Growth Factor (VEGF) and platelet-derived growth factor (PDGF) receptors. This prevents the tumor from developing its own blood supply. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Clinical Instructions & Administration To ensure maximum therapeutic efficacy and safety, follow these administration guidelines: Dosing Schedule: Sutinat is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Side Effects & Management Sutinat 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost-advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutykine 50 mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sutykine 50mg? Sutykine 50 mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. Classified as a multikinase inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that non-selectively attacks all rapidly dividing cells, Sutykine is designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sutykine Disrupts Cancer Sutykine 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases located on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sutykine stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sutykine targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Metastasis Suppression: By disrupting vital survival pathways, the medication helps slow the spread of malignant cells to other parts of the body. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sutykine is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Management of Potential Side Effects Sutykine 50 mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C. Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Partner with Ernest Impex? Ernest Impex, under the Ernest Pharmaceutical Pvt. Ltd. group, is a globally recognized pharmaceutical exporter from India, bridging the gap between life-saving Indian generics and global healthcare needs. ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sunisam 50mg Capsule (Sunitinib) Detailed Product Overview: What is Sunisam 50mg? Sunisam 50mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. It is classified as a multikinase inhibitor (TKI) and is a cornerstone in the field of targeted cancer therapy. Unlike traditional chemotherapy, which non-selectively attacks all rapidly dividing cells, Sunisam is designed to identify and interfere with specific molecular pathways involved in the growth, progression, and spread of cancer. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to imatinib. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer returning in high-risk patients following a nephrectomy. Mechanism of Action: How Sunisam Works Sunisam 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the biological infrastructure of a tumor. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals that tell the cancer cells to multiply. By blocking these signals, Sunisam halts uncontrolled cell division. Anti-Angiogenesis Strategy: Sunisam inhibits the Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This prevents the tumor from developing its own blood supply. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Clinical Instructions & Administration To ensure maximum therapeutic efficacy and safety, follow these administration guidelines: Dosing Schedule: Sunisam is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Side Effects & Management Sunisam 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Why Partner with Ernest Impex? Ernest Impex, under the Ernest Pharmaceutical Pvt. Ltd. group, is a globally recognized pharmaceutical exporter from India, bridging the gap between life-saving Indian generics and global healthcare needs. ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost-advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutib 50mg Capsule (Sunitinib) Detailed Product Overview: What is Sutib 50mg? Sutib 50 mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. It is classified as a multikinase inhibitor and is a cornerstone in the field of targeted cancer therapy. Unlike traditional chemotherapy, which non-selectively attacks rapidly dividing cells, Sutib is designed to identify and interfere with specific molecules involved in the growth, progression, and spread of cancer. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to imatinib. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer returning in high-risk patients following a nephrectomy. Mechanism of Action: How Sutib Works Sutib 50 mg operates through a sophisticated “multi-receptor“ blockade to dismantle the biological infrastructure of a tumor. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals that tell the cancer cells to multiply. By blocking these signals, Sutib halts uncontrolled cell division. Anti-Angiogenesis Strategy: Sutib inhibits the Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This prevents the tumor from developing its own blood supply. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Clinical Instructions & Administration To ensure maximum therapeutic efficacy and safety, follow these administration guidelines: Dosing Schedule: Sutib is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Side Effects & Management Sutib 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Why Partner with Ernest Impex? Ernest Impex, under the Ernest Pharmaceutical Pvt. Ltd. group, is a globally recognized pharmaceutical exporter from India, bridge-building the gap between life-saving Indian generics and global healthcare needs. ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutent 25mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sutent 25mg? Sutent 25mg is a potent, multi-targeted oral oncology medication containing the active pharmaceutical ingredient Sunitinib. Classified as a Tyrosine Kinase Inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that attacks all rapidly dividing cells, Sutent is designed to target specific molecular pathways that allow tumors to survive and thrive. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a first-line therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite imatinib therapy. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following a nephrectomy (kidney removal) in high-risk patients. Mechanism of Action: How Sutent Disrupts Cancer Sutent 25mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Anti-Angiogenesis Strategy: Sutent targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of the oxygen it needs to expand. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sutent is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 25mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to dangerous levels. Management of Potential Side Effects Sutent is a powerful medication and may cause adverse reactions. Early identification and management are key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Partner with Ernest Impex? Ernest Impex, under the Ernest Pharmaceutical Pvt. Ltd. group, is a globally recognized pharmaceutical exporter from India, building a bridge between life-saving Indian generics and global healthcare needs. ✔ GMP Standards: We supply only those products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383